The study, conducted with serial analysis of cell-free circulating tumour DNA (cfDNA) from three patients, showed that acquired resistance to infigratinib is correlated with point mutations in the FGFR2 kinase domain during progression [135]. Here, FGFR2 is linked to neoplasm.